BACKGROUND: Growing body of laboratory evidence supports the beneficial effects of n-3 polyunsaturated fatty acids (PUFAs) on colorectal cancer (CRC) prevention. Epidemiologic studies investigating the relationship between n-3 PUFAs intake and risk of CRC, however, have been inconsistent. We aimed to clarify the relation by conducting a meta-analysis of prospective studies. METHODS: Eligible studies were identified by searching PubMed database and by carefully reviewing bibliographies of retrieved publications. Summary relative risks (RRs) with their 95 % confidence intervals (CIs) were computed with a random-effects model. Subgroup, meta-regression, and dose-response analyses were performed to explore potential sources of heterogeneity. RESULTS: A total of 14 prospective studies involving 8,775 cancer cases were included in the final analysis. Overall, total n-3 or marine PUFAs intake was not associated with risk of CRC (RR 0.99 and 1.00). However, there was a trend toward reduced risk of proximal colon cancer (total n-3 PUFAs: RR 0.83, 95 % CI 0.66-1.05; marine PUFAs: RR 0.81, 95 % CI 0.59-1.10) and a significant increased risk of distal colon cancer (total n-3 PUFAs: RR 1.26, 95 % CI 1.06-1.50; marine PUFAs: RR 1.38, 95 % CI 1.11-1.71). Furthermore, marine PUFAs intake accessed longer before diagnosis was associated 21 % reduced risk of CRC (RR 0.79, 95 % CI 0.63-1.00). CONCLUSION: Overall, this meta-analysis finds no relation between n-3 PUFAs intake and risk of CRC. The observed subsite heterogeneity within colon cancer and the possible effect modification by latency time merit further studies.
BACKGROUND: Growing body of laboratory evidence supports the beneficial effects of n-3 polyunsaturated fatty acids (PUFAs) on colorectal cancer (CRC) prevention. Epidemiologic studies investigating the relationship between n-3 PUFAs intake and risk of CRC, however, have been inconsistent. We aimed to clarify the relation by conducting a meta-analysis of prospective studies. METHODS: Eligible studies were identified by searching PubMed database and by carefully reviewing bibliographies of retrieved publications. Summary relative risks (RRs) with their 95 % confidence intervals (CIs) were computed with a random-effects model. Subgroup, meta-regression, and dose-response analyses were performed to explore potential sources of heterogeneity. RESULTS: A total of 14 prospective studies involving 8,775 cancer cases were included in the final analysis. Overall, total n-3 or marine PUFAs intake was not associated with risk of CRC (RR 0.99 and 1.00). However, there was a trend toward reduced risk of proximal colon cancer (total n-3 PUFAs: RR 0.83, 95 % CI 0.66-1.05; marine PUFAs: RR 0.81, 95 % CI 0.59-1.10) and a significant increased risk of distal colon cancer (total n-3 PUFAs: RR 1.26, 95 % CI 1.06-1.50; marine PUFAs: RR 1.38, 95 % CI 1.11-1.71). Furthermore, marine PUFAs intake accessed longer before diagnosis was associated 21 % reduced risk of CRC (RR 0.79, 95 % CI 0.63-1.00). CONCLUSION: Overall, this meta-analysis finds no relation between n-3 PUFAs intake and risk of CRC. The observed subsite heterogeneity within colon cancer and the possible effect modification by latency time merit further studies.
Authors: Zora Djuric; Muhammad Nadeem Aslam; Becky R Simon; Ananda Sen; Yan Jiang; Jianwei Ren; Rena Chan; Tanu Soni; T M Rajendiran; William L Smith; Dean E Brenner Journal: J Nutr Biochem Date: 2017-04-25 Impact factor: 6.048
Authors: Joshua Petimar; Stephanie A Smith-Warner; Teresa T Fung; Bernard Rosner; Andrew T Chan; Frank B Hu; Edward L Giovannucci; Fred K Tabung Journal: Am J Clin Nutr Date: 2018-11-01 Impact factor: 7.045
Authors: Aurélie Moskal; Heinz Freisling; Graham Byrnes; Nada Assi; Michael T Fahey; Mazda Jenab; Pietro Ferrari; Anne Tjønneland; Kristina En Petersen; Christina C Dahm; Camilla Plambeck Hansen; Aurélie Affret; Marie-Christine Boutron-Ruault; Claire Cadeau; Tilman Kühn; Verena Katzke; Khalid Iqbal; Heiner Boeing; Antonia Trichopoulou; Christina Bamia; Androniki Naska; Giovanna Masala; Maria Santucci de Magistris; Sabina Sieri; Rosario Tumino; Carlotta Sacerdote; Petra H Peeters; Bas H Bueno-de-Mesquita; Dagrun Engeset; Idlir Licaj; Guri Skeie; Eva Ardanaz; Genevieve Buckland; José M Huerta Castaño; José R Quirós; Pilar Amiano; Elena Molina-Portillo; Anna Winkvist; Robin Myte; Ulrika Ericson; Emily Sonestedt; Aurora Perez-Cornago; Nick Wareham; Kay-Tee Khaw; Inge Huybrechts; Konstantinos K Tsilidis; Heather Ward; Marc J Gunter; Nadia Slimani Journal: Br J Cancer Date: 2016-10-20 Impact factor: 7.640
Authors: Christina Steppeler; Marianne Sødring; Bjørg Egelandsdal; Bente Kirkhus; Marije Oostindjer; Ole Alvseike; Lars Erik Gangsei; Ellen-Margrethe Hovland; Fabrice Pierre; Jan Erik Paulsen Journal: PLoS One Date: 2017-04-20 Impact factor: 3.240
Authors: Aesun Shin; Sooyoung Cho; Sven Sandin; Marie Lof; Moon Young Oh; Elisabete Weiderpass Journal: Cancer Res Treat Date: 2020-03-06 Impact factor: 4.679
Authors: Keum Hwa Lee; Hyo Jin Seong; Gaeun Kim; Gwang Hun Jeong; Jong Yeob Kim; Hyunbong Park; Eunyoung Jung; Andreas Kronbichler; Michael Eisenhut; Brendon Stubbs; Marco Solmi; Ai Koyanagi; Sung Hwi Hong; Elena Dragioti; Leandro Fórnias Machado de Rezende; Louis Jacob; NaNa Keum; Hans J van der Vliet; Eunyoung Cho; Nicola Veronese; Giuseppe Grosso; Shuji Ogino; Mingyang Song; Joaquim Radua; Sun Jae Jung; Trevor Thompson; Sarah E Jackson; Lee Smith; Lin Yang; Hans Oh; Eun Kyoung Choi; Jae Il Shin; Edward L Giovannucci; Gabriele Gamerith Journal: Adv Nutr Date: 2020-09-01 Impact factor: 8.701